PointState Capital LP Has $39.01 Million Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

PointState Capital LP trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 19.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,297,449 shares of the company's stock after selling 810,403 shares during the period. Roivant Sciences accounts for about 0.7% of PointState Capital LP's portfolio, making the stock its 28th biggest holding. PointState Capital LP owned approximately 0.45% of Roivant Sciences worth $39,009,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in ROIV. Barclays PLC raised its stake in Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after acquiring an additional 75,609 shares during the period. Wedmont Private Capital acquired a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $134,000. Miracle Mile Advisors LLC bought a new position in Roivant Sciences during the 4th quarter worth $148,000. Penn Davis Mcfarland Inc. increased its position in Roivant Sciences by 1.0% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 1,649,026 shares of the company's stock worth $19,508,000 after buying an additional 16,832 shares during the period. Finally, Impact Partnership Wealth LLC bought a new position in Roivant Sciences during the 4th quarter worth $222,000. 64.76% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on ROIV. HC Wainwright reiterated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 21st. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.

Roivant Sciences Stock Up 1.0%

Shares of ROIV traded up $0.11 during trading hours on Tuesday, hitting $10.95. 1,194,321 shares of the company were exchanged, compared to its average volume of 5,566,947. The company has a market cap of $7.81 billion, a price-to-earnings ratio of -72.90 and a beta of 1.23. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $13.06. The firm's fifty day moving average is $10.51 and its 200 day moving average is $11.07.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 434,478 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $10.82, for a total value of $4,701,051.96. Following the sale, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at $12,197,277.80. This trade represents a 27.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the firm's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares in the company, valued at $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,223,959 shares of company stock valued at $13,420,035 over the last ninety days. 7.90% of the stock is owned by corporate insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.